The AAV9-CaMKIIα0.4 vector eliminated viral shedding in 90% of treated eyes and reduced TG HSV-1 DNA by 51%. The presentations can be accessed on the Excision website at ...

LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

The event brought together thought leaders advancing health-system pharmacy in the management, delivery, and optimization of advanced therapeutics.

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional ...

Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs).

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation ...

Preeclampsia is a complication characterised by high blood pressure and organ damage, arising during the second half of ...

Early detection is key to survival, but requires urgent awareness, better healthcare access, and Africa-specific genetic ...

Domus Pacis Family Respite, a Frisco-based non-profit organization, sets up cancer patients and their families with vacations ...